Products Affected - Description
Esmolol injection, West-Ward
10 mg/mL single-dose vial, package of 10 (NDC 55390-0062-10)
Reason for the Shortage
West-Ward Pharmaceuticals’ parent company, Hikma Pharmaceuticals, acquired esmolol injection from Bedford in July 2014. West-Ward is not actively marketing esmolol injection at this time.
Brevibloc premix, Baxter
10 mg/mL, 250 mL, package of 10 (NDC 10019-0055-61)
20 mg/mL, 100 mL, package of 10 (NDC 10019-0075-87)
Esmolol injection, Baxter
10 mg/mL, 10 mL single-dose vial, package of 25 (NDC 10019-0120-01)
10 mg/mL, 10 mL single-dose vial, package of 100 (NDC 10019-0115-01)
Esmolol injection, Fresenius Kabi
10 mg/mL, 10 mL single-dose vial, package of 25, NDC 63323-0652-10
Esmolol injection, Mylan Institutional
10 mg/mL, 10 mL single-dose vial, package of 10, NDC 67457-0182-10
Estimated Resupply Dates
All marketed presentations are available at this time.
April 7, March 9, February 12 and 24, January 16, 2015; November 6, August 8, May 8, February 5, 2014; December 18, November 6, October 24, September 3 and 12, July 10 and 18, May 10 and 22, March 14, February 13, January 2 and 11, 2013; December 14, November 2, October 4, September 12, July 25, June 5, May 8 and 21, April 4,12, and 23, March 19, February 16 and 29, January 6, 2012; December 2, October 4 and 19, September 21, 2011, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins